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Introduction
The recently identified G protein coupled receptor 109A (GPR109A) is now recognized as the molecular target that mediates the long established anti-hyperlipidemic effect of nicotinic acid (NA) (Canner et al., 1986; Carlson, 2005) . The most common side effect of NA is the prostaglandinsdependent flushing reaction (Andersson et al., 1977; Morrow et al., 1989) . The latter involves intracellular Ca 2+ elevation and subsequent activation of phospholipase A2 (Lin et al., 1992; Benyo et al., 2006) . In the CNS, higher intracellular Ca 2+ levels enhance neurotransmitters release, including glutamate (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004) .
GPR109A is widely expressed in white and brown adipose tissue, keratinocytes and various immune cells including monocytes, macrophages, neutrophils and dendritic cells including Langerhans cells (Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003; Hanson et al., 2010) , and likely in microglia (Penberthy, 2009) . Despite NA ability to enter the brain (Spector, 1979) , there are no reports on the expression or function of GPR109A in cardiovascular regulating nuclei including the RVLM. The latter sends excitatory input to the sympathetic preganglionic neurons, and regulate the sympathetic nervous system and peripheral cardiovascular activity (Ciriello et al., 1986; Chapp et al., 2014) .
Realizing that NA activation increases intracellular Ca 2+ in other cell types (Benyo et al., 2006) , it is likely that access of NA to central GPR109A might produce a similar effect and triggers Lglutamate release in the RVLM, which is Ca 2+ -dependent (Tingley and Arneric, 1990) . L-glutamate activation of fast-acting ionotropic receptors, including NMDA and AMPA receptors increases intracellular Na + and Ca 2+ as well as nerve firing (Dingledine et al., 1999) . While the L-glutamate activation of the central ionotropic or the metabotropic receptors (Gabor and Leenen, 2012) causes sympathoexcitation and a pressor response (Ito et al., 2003) , the NMDA receptor (NMDAR)mediated fast and brief pressor response prevails in the RVLM (Kubo et al., 1993) . Further, This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 30, 2015 as DOI: 10.1124 at ASPET Journals on November 4, 2016 jpet.aspetjournals.org Downloaded from JPET #229146 5 elevations in Ca 2+ (Lipton and Rosenberg, 1994) and L-glutamate (Albrecht et al., 2010 ) levels lead to oxidative stress, and the occurrence of the latter in the RVLM leads to sympathoexcitation and pressor response (Nishihara et al., 2012) .
In the present study, we tested the hypothesis that Ca 2+ -dependent L-glutamate release and oxidative stress, triggered by NA activation of RVLM GPR109A, causes sympathoexcitation and a pressor response. We adopted a multilevel approach, which included pharmacological cardiovascular studies in conscious rats complemented with ex vivo and in vitro molecular studies.
We conducted the detailed molecular studies in vitro, because the tissue scarcity and the rapid onset of the NA-evoked pressor response precluded conducting detailed ex vivo studies on RVLM tissue. Importantly, differentiated PC12 cells, used in these studies, exhibit a sympathetic-neuronlike phenotype (Greene, 1978; Penugonda et al., 2005) . Following the first demonstration of GPR109A expression in the RVLM and in PC12 cells, we investigated the effects of intra-RVLM NA, or its inactive isomer iso-nicotinic acid (IsoNA), on BP and heart rate (HR) in conscious rats.
Additional in vivo studies were conducted in the presence of NMDAR blockade (2-amino-5phosphonopentanoic acid; AP5), non-NMDAR (AMPA/Kainate) blockade (6-cyano-7nitroquinoxaline-2,3-dione; CNQX) or L-glutamate uptake inhibition (L-trans-Pyrrolidine-2,4dicarboxylic acid; PDC) in the RVLM. The effects of these pharmacological interventions or GPR109A knockdown (siRNA) on the GPR109A (NA)-mediated biochemical responses were also investigated in PC12 cells to complement, and to mechanistically explain, the in vivo findings. 
Measurement of Oxidative Stress.
We used 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes, Grand Island, NY), a general detector of oxidative species, to measure oxidative stress in PC12 cells and in RVLM specimens taken from animals that received NA or its vehicle. Further, the dihydroethidium (DHE) staining method, which is more superoxide anion selective (Bindokas et al., 1996; Robinson et al., 2006) was used for ROS measurements in RVLM sections of animals that received the different treatments described below. The methods and protocols used are detailed in our previous studies (Penumarti and Abdel-Rahman, 2014) protocol. A substantial (≈70%) reduction in GPR109A expression (western blot) validated the adopted siRNA knockdown strategy.
Experimental Design and Protocols
Experiment 1: Expression of GPR109A in the RVLM and PC12 Cells.
The objective of this experiment was to determine if GPR109A is expressed in the RVLM and in PC12 cells, and its spatial distribution in the RVLM relative to different cell types, particularly tyrosine hydroxylase (TH) immunoreactive (ir) neurons, which modulate the sympathetic activity and BP (Guyenet, 2006; Kumagai et al., 2012) . First, western blot (WB) analysis was conducted to detect GPR109A in PC12 cell lysate, and in punches taken from the RVLM of naïve rats (n = 3). Tissues rich in (spleen), or devoid of (liver) GPR109A (Soudijn et al., 2007) were used as positive and negative controls, respectively, in these studies. Second, dual labeled immunofluorescence (IF) was conducted in post-fixed sections from rat frozen brains and PC12 cells. Neuronal and glial cell markers including the neuronal marker, NeuN, the astrocyte marker, GFAP, and the microglia marker, CD11b/c were used to investigate the spatial distribution of GPR109A in different cell types in the RVLM. Further the expression of GPR109A relative to TH-ir neurons was investigated by using an anti-tyrosine hydroxylase antibody. We followed methods described in our previous studies (Ibrahim and Abdel-Rahman, 2011;
Penumarti and Abdel-Rahman, 2014) and detailed in the online supplemental material.
Experiment 2: Functional Role of RVLM GPR109A in BP and HR Regulation.
As there are no reported studies on intra-RVLM NA, a preliminary study was conducted to determine the optimal NA dose to be used throughout the study based on estimated penetration of systemic NA into the CNS (Spector, 1979) . Two groups of conscious unrestrained SD rats (n = 4-7), instrumented for BP and HR measurements and RVLM microinjections as detailed under methods, received intra-RVLM NA (5, 10 and 20 μ g/animal) or the vehicle, artificial This article has not been copyedited and formatted. The final version may differ from this version. cerebrospinal fluid (ACSF). The 20 µg NA dose, which produced consistent pressor response, was used in subsequent studies. There are currently no GPR109A antagonists. Therefore, to ensure that the NA-evoked pressor response was GPR109A mediated, the same dose (20 μ g/animal) of the NA inactive isomer, IsoNA, was microinjected into the RVLM of a third group of rats (n = 6).
Experiment 3: Effect of NMDAR, non-NMDAR Blockade or L-glutamate Uptake
Inhibition on the Cardiovascular Effects of NA.
The role of L-glutamate in NA-induced pressor response was investigated using different pharmacological interventions in conscious male SD rats instrumented for measurements of BP and HR and RVLM microinjections as detailed under methods. Four groups of rats (n = 5-7)
received the NMDAR blocker, AP5 (2 nmol/100nl) (Zhang and Abdel-Rahman, 2002) , the non-NMDAR blocker, CNQX (200 pmol) (Wang et al., 2007) , the glutamate uptake inhibitor, PDC (1 µM) (Montiel et al., 2005) or ACSF 10 min before NA (20 μ g/animal) microinjection.
Experiment 4: GPR109A-dependent Biochemical Effects of NA.
The objective of this experiment was to obtain direct biochemical evidence that GPR109A mediates elevations in L-glutamate release, intracellular Ca 2+ and reactive oxygen species (ROS), which are implicated in sympathoexcitation and BP elevation (Lipton and Rosenberg, 1994; Ito et al., 2003; Nishihara et al., 2012) . PC12 cells, used as surrogates of RVLM neurons, PC12 following GPR109A knockdown with siRNA (see methods). The pharmacological interventions incubated with PC12 cells in the absence or the presence of NA (1 mM) included:
(i) L-glutamate in a concentration (100 nM) that was achieved 1 min after NA (1 mM) addition to PC12 (preliminary experiment); (ii) the glutamate uptake inhibitor, PDC (0.1 mM) for 1 h (Pepponi et al., 2009 ); (iii) the NMDAR blocker, AP5 (100 μ M) for 10 min (Reigada et al., 2006) .
For ex vivo ROS measurements, brain tissues were collected from animals (n = 4-5 rats) that received the different treatments following euthanasia with a lethal dose of pentobarbital sodium (>100 mg/kg) at the end of BP recording period. Fresh unfixed brainstem sections (20 µm) sections were taken followed by collecting micropunches from the injected RVLM side using a 0.75 micropunch instrument (Stoelting Co., Wood Dale, IL), using the following coordinates 12.6
to -11.8 mm relative to bregma as in reported studies including ours (Paxinos et al., 1980;  Ibrahim and Abdel-Rahman, 2015).
Drugs.
NA, L-glutamate, and PDC were purchased from Sigma-Aldrich (St. Louis, MO 
Results
GPR109A Co-expression with Tyrosine Hydroxylase in the RVLM and in PC12 Cells.
WB analysis revealed and verified the expression GPR109A in the RVLM and PC12 cells, when compared to tissues rich in (spleen) or devoid of (liver) GPR109A expression ( Fig. 1A) .
Further, dual-labeled IF findings in PC12 cells showed co-expression of GPR109A and TH (Fig.   1B ). Cell type specific labeling ( Fig. 2 A-D) , and quantitative comparisons of GPR109A expression in different cell types revealed much greater percentage (approx. 70%) of the counted neuronal than non-neuronal (astrocytes and microglia) (30%) cells of the RVLM expressed GPR109A. Further, the majority (>90%) of the RVLM TH-ir neurons also expressed GPR109A ( Fig. 2E ).
Activation of RVLM GPR109A Causes Glutamate-like Pressor Response and Neuronal Oxidative
Stress.
BP and HR values before intra-RVLM microinjection of NA in the absence or presence of pharmacologic interventions, indicated below, were not significantly different (Table 1) . Intra-RVLM NA (5, 10, 20 µg) caused dose-dependent pressor response and bradycardia in conscious rats (Fig. 3) . These cardiovascular responses resembled the responses elicited by intra-RVLM L-glutamate (1 nmol; 169 ng) ( Fig. 3A) . Importantly, the inactive NA isomer, IsoNA (20 µg), failed to influence BP or HR (Fig. 4, A and B ). Ex vivo studies revealed higher ROS levels in NA (20 µg)-treated RVLM, but not following the same dose of IsoNA (Fig. 5 ).
Selective NMDAR Blockade and Glutamate Uptake Inhibition Abrogates and Enhances,
Respectively, the Intra-RVLM NA-Evoked Oxidative Stress and Pressor Response.
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1 2 increased the magnitude and duration (presented as area under the curve, AUC) of the pressor response ( Fig. 4 , C and E) and exacerbated the elevation in RVLM ROS (Fig. 5B ) caused by subsequent intra-RVLM NA (20 µg) microinjection. None of these intervention changed BP or HR from the corresponding baseline values (Table 1) .
GPR109A Activation Increases L-glutamate, Ca 2+ and NO levels and Produces NMDAR-Dependent Oxidative Stress in PC12 cells.
The rapid onset (approx. 1 min) of the pressor response caused by intra-RVLM NA precluded measurements of RVLM L-glutamate, Ca 2+ and NO levels during this timeframe. Therefore, such measurements were made in differentiated PC12 cells, which exhibit neuronal phenotype and express GPR109A (Fig. 1, A and B ). NA (100 μ M or 1mM) significantly (P < 0.05) increased Ca 2+ (Fig. 6A ), L-glutamate (Fig. 6B) , and NO (Fig. 6C ) levels 30-60 sec after NA addition to the incubation medium. Pre-incubating PC12 cells with the L-glutamate uptake inhibitor PDC (0.1 mM/1 h) significantly (P < 0.05) enhanced NA-evoked glutamate release (Fig. 6B) . These biochemical responses were associated with significant (P < 0.05) increases in ROS levels (Fig.   7A ). Notably, L-glutamate, in a concentration (100 nM), detected after NA (1 mM) addition to incubation medium (preliminary), significantly (P <0.05) increased ROS level (Fig. 7B ). Similar to ex vivo findings on RVLM (Fig. 5) , the NA-induced oxidative stress was circumvented by prior NMDAR blockade with AP5 (100 μ M) ( Fig. 7B) . Further, the inactive NA isomer, IsoNA (1 mM), had no effect on Ca 2+ , glutamate, NO (Fig. 6, A, B and C) or ROS (Fig. 7A ) levels.
GPR109A Knockdown Abolishes NA Induced Ca 2+ and Glutamate Release in PC12 Cells.
There are no available GPR109A antagonists. Therefore, we used siRNA knockdown strategy to validate the involvement of GPR109A in the NA-evoked biochemical responses in PC12 cells, described above. The GPR109A targeting siRNA significantly (P < 0.05) reduced GPR109A expression ( Fig. 8A) . In PC12 cells pretreated with the negative siRNA control (scrambled siRNA), NA (1 mM) significantly (P < 0.05) increased Ca +2 (Fig. 8B ) and glutamate ( Fig. 8C ) levels. However, in PC12 cells, which exhibited significant (P < 0.05) siRNA-induced reduction in GPR109A expression ( Fig. 8A) , NA (1 mM) failed to produce these biochemical responses (Fig. 8, B and C) .
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Discussion
In this study we tested the hypothesis that NA activation of RVLM GPR109A induces Lglutamate (NMDAR)-dependent oxidative stress and sympathoexcitation/pressor response. We focused on the RVLM because it mediates L-glutamate-dependent increases in sympathetic activity and BP, and tonically regulates the peripheral vascular activity (Ciriello et al., 1986; Bazil and Gordon, 1993; Chapp et al., 2014) .
Our most important findings are: (i) the majority of RVLM neurons, and particularly the TH-ir neurons, express GPR109A; (ii) intra-RVLM injection of the GPR109A agonist NA, but not its inactive isomer ( GPR109A, which serves as a receptor for NA (Soga et al., 2003; Tunaru et al., 2003) , is expressed in adipose tissue and immune cells (Soga et al., 2003; Maciejewski-Lenoir et al., 2006; Penberthy, 2009 ). Under normal physiological conditions, the levels of the endogenous agonist (β-hydroxybutyrate) or exogenous agonist (NA), when taken as a vitamin, might be lower than the μM-mM concentration range needed to activate GPR109A (Taggart et al., 2005) .
However, when used in much higher doses as anti-hyperlipidemic drug (Brown et al., 2001; Whitney et al., 2005) , such NA concentrations might be achieved. Further, despite evidence that NA is transported into the brain in appreciable concentrations following systemic administration (Spector, 1979) , there are no reports on GPR109A expression or function in neuronal structures, which regulates sympathetic outflow and BP (e.g. RVLM). Here, we present the first JPET #229146
1 5 evidence that GPR109A is expressed in RVLM neurons, including the TH expressing neurons (Fig. 2, A and B) ; the latter modulate the sympathetic activity and BP (Guyenet, 2006; Kumagai et al., 2012) . These findings, which infer a cardiovascular role for GPR109A, were confirmed by observing dose-related increases in BP following intra-RVLM NA microinjection in conscious rats (Fig. 3B) . The rapid onset of the NA-induced pressor response along with the associated bradycardia were reminiscent of cardiovascular responses elicited by L-glutamate microinjection into the same neuronal pool observed in a separate group of rats (Fig. 3A) , and in reported studies including ours (Bachelard et al., 1990; Mao and Abdel-Rahman, 1994) . While the rapid onset of the pressor response (Fig. 3A) precluded investigation of NA effect on RVLM Lglutamate release, we adopted pharmacological approaches in vivo and direct biochemical measurements in PC12 cells to support L-glutamate involvement in the NA-evoked cardiovascular responses. It is imperative, nonetheless, to note that these cardiovascular responses were mediated via NA activation of RVLM GPR109A because the inactive NA isomer, IsoNA, failed to produce similar cardiovascular effects (Fig. 4, A and B ).
We hypothesized that NA activation of GPR109A in the RVLM leads to Ca 2+ -dependent Lglutamate release because: (i) NA (10 µM-3 mM) mediates GPR109A dependent increase in intracellular Ca 2+ levels in macrophages and epidermal Langerhans cells (Benyo et al., 2005; Benyo et al., 2006; Vanhorn et al., 2012; Gaidarov et al., 2013) , (ii) Ca 2+ triggers L-glutamate release (Kish and Ueda, 1991; Berridge, 1998; Sudhof, 2004) , and (iii) elevated L-glutamate levels cause oxidative stress (Wang et al., 2013; Yang et al., 2014 ), sympathoexcitation (Chapp et al., 2014 , and ultimately BP elevation (Iwata et al., 1987; Bazil and Gordon, 1993) .
Therefore, the RVLM GPR109A most likely mediates a glutamate-dependent sympathoexcitation. Although the origin of NA-induced glutamate release in the RVLM remains uncertain, the RVLM presympathetic neurons contribute, at least partly to this process because they exhibit the highest GPR109A level in the RVLM (Fig. 2E) , and their axonal varicosities contain the glutamate transporter VGLUT2, and release glutamate (DePuy et al., 2013) . Our in vivo and ex vivo findings supported the L-glutamate hypothesis because local NMDAR blockade (AP5) abrogated, while glutamate uptake inhibition (PDC) exacerbated, the pressor response ( Fig. 4) and RVLM oxidative stress (Fig. 5) caused by intra-RVLM NA.
Next, we leveraged the biological phenotype resemblance of the differentiated PC12 cells and RVLM neurons (Separovic et al., 1997; Zhang et al., 2001) to obtain direct evidence that NA activation of GPR109A leads to L-glutamate and Ca 2+ release. However, in the absence of any reports on GPR109A expression in PC12 cells, it was important to determine if, similar to the RVLM neurons, the receptor is expressed, and is spatially associated with TH, in this cell line. Our WB and dual labeling IF (Fig. 1, A and B ) confirmed our assumptions, and validated the use of differentiated PC12 cells as an appropriate model system for studying the biochemical events triggered by NA activation of GPR109A. We showed that NA causes increases in Ca 2+ and L-glutamate levels in PC12 cells (Fig. 6, A and B ) along with oxidative stress (Fig. 7A ).
It was important to determine if the GPR109A-mediated increase in glutamate release (Fig.   6B ) accounts for the oxidative stress (Fig. 7A ) because the latter is implicated in sympathoexcitation as discussed above. Our findings support this view because: (i) NA (1 mM) and L-glutamate, in a concentration (100 nM) similar to that released by NA (1 mM), produced comparable increases in oxidative stress in PC12 cells (Fig. 7B) ; (ii) L-glutamate uptake inhibition augmented the NA-induced glutamate release (Fig. 6B) . Although no GPR109A
antagonists are currently available, these effects are most likely GPR109A-dependent because the inactive NA isomer IsoNA, whose microinjection into the RVLM had no effect on BP or RVLM redox state (Figs. 4 and 5) , also failed to reproduce NA-evoked biochemical effects in PC12 cells (Figs. 6 and 7) . The latter findings agree with reported studies in other model systems (Maciejewski-Lenoir et al., 2006; Gaidarov et al., 2013) . Equally important, NA failed to increase Ca 2+ or glutamate levels in PC12 cells following siRNA-evoked GPR109A knockdown ( Fig. 8) , which provided direct evidence for GPR109A mediation of NA actions, and support the in vivo findings, discussed above.
It is important to comment on the role of the NMDAR in mediating the biochemical and pressor responses caused by NA activation of GPR109A. As discussed above, NA activation of GPR109A leads to the release of L-glutamate, which activates ionotropic and metabotropic glutamate receptors (Gabor and Leenen, 2012) . The rapid onset of the NA-evoked pressor response is consistent with L-glutamate activation of the NMDAR ionotropic receptors in the RVLM (Kubo et al., 1993) . This assumption was confirmed by the ability of the NMDAR blocker AP5 (Fig. 4C) , but not the non-NMDAR blocker CNQX (Fig. 4E) , to abrogate the NA-evoked pressor response as well as oxidative stress (Fig. 5B) . Further, NMDAR activation by Lglutamate mediates a Ca 2+ /calmodulin-dependent nNOS-derived NO generation and neurotoxicity (Garthwaite et al., 1988; Dawson et al., 1993) . There is also evidence that NO is involved in glutamate-mediated neurotransmission in different brain areas (Southam et al., 1991; Montague et al., 1994) including the RVLM (Martins-Pinge et al., 1999) . Additionally, the nNOS-derived NO in the RVLM causes sympathoexcitation in reported studies including ours (Martins-Pinge et al., 2007; Ibrahim and Abdel-Rahman, 2012) . Therefore, It is likely that the increased levels of NO by NA (0.01-1mM) in PC12 cells (Fig. 6C ) levels, which agrees with a reported finding in cultured endothelial cells treated with similar (0.5-2mM) NA concentrations (Huang et al., 2012) , is probably due to the activation of NMDAR, via GPR109A mediated glutamate release. Notably, higher NO levels can contribute to RVLM oxidative stress via its interaction with elevated superoxide levels, detected by DHE staining in the RVLM of NA treated rats (Fig. 5B) , to produce peroxynitrite radical (Beckman et al., 1990) , which causes dosedependent transient excitatory responses when injected into the RVLM (Zanzinger, 2002) .
Conversely, others reported that intra-RVLM injection of NO precursor or donor decreases sympathetic nerve activity and BP (Kagiyama et al., 1997) . Therefore, the possibility must be considered that the GPR109A-mediated increase in NO levels could either contribute to, or oppose, the pressor effect of intra-RVLM NA.
In conclusion, the present study presents the first evidence for GPR109A expression in the RVLM, and its mediation of sympathoexcitation and elevation of BP via glutamate/NMDARdependent mechanisms (Fig. 9 ). The complementary pharmacologic and biochemical findings clearly implicate the GPR109A in the observed responses. The present pharmacological findings might have clinical relevance in situations where high doses of NA are prescribed for the treatment of hyperlipidemia. Further, the present findings might have pathophysiological ramifications, particularly in hypertension for two reasons. First, there is a clear link between an exacerbated RVLM neuronal oxidative stress and the elevated BP in hypertension (Wu et al., 2014) . Second, compared to normotensive controls, activation of RVLM NMDAR causes greater elevation in BP in spontaneously hypertensive rats (Lin et al., 1995) . Collectively, the present findings, along with these reported studies, highlight central GPR109A as molecular target for the development of novel antihypertensive medications.
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Legends for Figures
